Traitement « à la carte » de l’hépatite chronique B

[1]  V. Leroy,et al.  Le patient atteint d’hépatite chronique B non contrôlé , 2008 .

[2]  Y. Benhamou.  Traitement de l'hépatite chronique B chez les patients co-infectés par le VIH , 2008 .

[3]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[4]  P. Marcellin,et al.  Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[5]  J. Desenclos,et al.  Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. , 2008, Journal of hepatology.

[6]  Y. Bacq.  [Hepatitis B and pregnancy]. , 2008, Gastroenterologie clinique et biologique.

[7]  M. Bourlière,et al.  Traitement de l’hépatite chronique B : nouvelles perspectives , 2008 .

[8]  F. Zoulim,et al.  Associations thérapeutiques dans la prise en charge des hépatites chroniques B , 2008 .

[9]  A. Vallet-Pichard,et al.  Hépatite chronique B : situations rares : dialyse, transplantation rénale et traitements pré-emptifs en situation d’immunosuppression , 2008 .

[10]  D. Samuel.  Transplantation hépatique pour hépatite chronique B , 2008 .

[11]  J. Pawlotsky.  Les techniques virologiques de diagnostic et de suivi de l’hépatite B , 2008 .

[12]  J. Cadranel,et al.  Peut-on arrêter un traitement par analogue nucléos(t)idique chez un malade atteint d’hépatite chronique B ? , 2008 .

[13]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[14]  M. Levrero,et al.  [502] ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IS SUPERIOR TO ADEFOVIR MONOTHERAPY FOR LAMIVUDINE-RESISTANT PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B , 2007 .

[15]  B. McMahon,et al.  Chronic hepatitis B. , 2002, The New England journal of medicine.

[16]  J. Stockman,et al.  A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B , 2007 .

[17]  J. Stockman,et al.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B , 2007 .

[18]  D. Snydman.  A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B , 2007 .

[19]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[20]  F. Zoulim.  [Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]. , 2006, Gastroentérologie Clinique et Biologique.

[21]  J. Zarski.  [Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient]. , 2006, Gastroentérologie Clinique et Biologique.

[22]  P. Couzigou,et al.  [Managing resistance to analogue antiviral drugs in a chronic compensated hepatitis B patient]. , 2006, Gastroentérologie Clinique et Biologique.

[23]  J. Cadranel.  [Clinical consequences of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]. , 2006, Gastroentérologie Clinique et Biologique.

[24]  Y. Benhamou.  [Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients]. , 2006, Gastroentérologie Clinique et Biologique.

[25]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[26]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[27]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[28]  M. Mohamadnejad.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2006, Archives of Iranian medicine.

[29]  T. Asselah,et al.  Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. , 2005, Journal of hepatology.

[30]  T. Asselah,et al.  Treatment of chronic hepatitis B , 2005, La Revue du praticien.

[31]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[32]  Yao Guang.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China , 2005 .

[33]  F. Zoulim.  Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. , 2004, Antiviral research.

[34]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[35]  P. Marcellin,et al.  A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B , 2004, Hepatology.

[36]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[37]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[38]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[39]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[40]  P. Marcellin.  EASL International Consensus Conference on Hepatitis C , 1999 .